Country: Canada
Language: English
Source: Health Canada
ROSIGLITAZONE (ROSIGLITAZONE MALEATE)
TEVA CANADA LIMITED
A10BG02
ROSIGLITAZONE
8MG
TABLET
ROSIGLITAZONE (ROSIGLITAZONE MALEATE) 8MG
ORAL
30/100/500
Prescription
THIAZOLIDINEDIONES
Active ingredient group (AIG) number: 0138802004; AHFS:
CANCELLED PRE MARKET
2015-10-16
_ _ _TEVA-ROSIGLITAZONE Tablets 2 mg, 4 mg and 8 mg _ _Page 1 of 53_ PRODUCT MONOGRAPH PR TEVA-ROSIGLITAZONE rosiglitazone (as rosiglitazone maleate) 2 mg, 4 mg and 8 mg Tablets Professed Standard Antidiabetic Agent Teva Canada Limited. 30 Novopharm Court Toronto, Ontario M1B 2K9 Date of Revision May 10, 2011 Submission Control No: 146250 _ _ _TEVA-ROSIGLITAZONE Tablets 2 mg, 4 mg and 8 mg _ _Page 2 of 53_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS................................................................................. 5 ADVERSE REACTIONS................................................................................................... 9 DRUG INTERACTIONS ................................................................................................. 14 DOSAGE AND ADMINISTRATION............................................................................. 16 OVERDOSAGE ............................................................................................................... 17 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 18 STORAGE AND STABILITY......................................................................................... 24 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 24 PART II: SCIENTIFIC INFORMATION .............................................................................. 25 PHARMACEUTICAL INFORMATION......................................................................... 25 CLINICAL TRIALS..................................................................................... Read the complete document